Acadia
  • Home
  • Contact
  • Home
  • About
    • Management Team
    • Board Of Directors
    • Our Purpose, Mission & Values
    • History
  • Product
  • Pipeline
    • Dementia-Related Psychosis
    • Rett Syndrome
    • Schizophrenia – Negative Symptoms
    • Early Stage Clinical Programs
  • Resources
    • Parkinson’s Disease Psychosis
    • Clinical Trials
    • Investigator Initiated Studies
    • Medical Education Grants
    • Scientific Publications
    • Compliance
  • Partnering
  • Investors
    • Stock Information
    • News Releases
    • Events & Presentations
    • Sec Filings
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • Annual Report and Proxy
    • Information Request
    • Email Alerts
  • Media
  • Careers
    • Current Openings
  • Contact
  • About
    • Management Team
    • Board Of Directors
    • Our Purpose, Mission & Values
    • History
  • Product
  • Pipeline
    • Dementia-Related Psychosis
    • Rett Syndrome
    • Schizophrenia – Negative Symptoms
    • Early Stage Clinical Programs
  • Resources
    • Parkinson’s Disease Psychosis
    • Clinical Trials
    • Investigator Initiated Studies
    • Medical Education Grants
    • Scientific Publications
    • Compliance
  • Partnering
  • Investors
    • Stock Information
    • News Releases
    • Events & Presentations
    • Sec Filings
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • Annual Report and Proxy
    • Information Request
    • Email Alerts
  • Media
  • Careers
    • Current Openings
  • About
  • Management Team
  • Board Of Directors
  • Our Purpose, Mission & Values
  • History

Acadia is trailblazing breakthroughs in neuroscience to elevate life.

Acadia aspires to enable brighter moments for patients and their loved ones. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most.

We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
For more information, follow us on LinkedIn.

News

May 4, 2022
Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results

Company Information

Annual Report
Events & Presentations

Publication Spotlight

Pimavanserin for patients with Parkinson’s disease psychosis: a randomized, placebo-controlled phase 3 trial. The Lancet, 383, 533-540 (2014).

Parkinson’s disease psychosis, which includes hallucinations and delusions, is frequent and debilitating in people with Parkinson’s disease. We aimed to assess safety and efficacy of pimavanserin, a selective serotonin 5-HT2A inverse agonist, in this population.

Link to full article
  • Print page
  • Share
  • Privacy
  • Cookies
  • Privacy
    Shield
  • Terms
  • Email

© 2022 Acadia Pharmaceuticals Inc. Acadia and NUPLAZID are registered trademarks of Acadia Pharmaceuticals Inc. All rights reserved.

This website uses cookies to improve and customize your experience on our website. By using this website without changing your cookie settings in your browser, you agree to our use of cookies. For further details on cookies, how we use cookies and how to delete or block the use of cookies, please read our Cookie Policy.

ACCEPT